VEGFA and neoplasm: Additionally, in Model 4, adjusted for BMI, parity, menopausal status, smoking status, disease stage, tumor diameter, intrinsic type, histological type, and nodal involvement, higher pre-treatment levels of VEGF-A were associated with an increased risk of BrC recurrence (standardized β 0.2958, p = 0.0308).